Mutation studies have revealed ARID2 to be a significant
tumor suppressor in many cancer subtypes.
ARID2 mutations are prevalent in
hepatocellular carcinoma and
melanoma. Mutations are present in a smaller but significant fraction in a wide range of other tumors.
ARID2 mutations are enriched in
hepatitis C virus-associated hepatocellular carcinoma in the US and European patient populations compared with the overall
mutation frequency. ==References==